Podcasts about phase2

This week: 109 days into a ceasefire, Israel has killed at least 646 Palestinians in Gaza. The US announced phase 2 of the Gaza ceasefire deal. Israeli forces kill a young boy in the Occupied West Bank. Israel has killed more than 71,548 Palestinians in Gaza since October 7th, 2023. In this episode: Osama Bin Javid, (@osamabinjavaid), Al Jazeera Correspondent Michael Appel, (@TheMikeAppel), Al Jazeera Senior Producer Tareq Abu Azzoum, (@abuoazzum) Al Jazeera Correspondent Nida Ibrahim, (@nidaibrahim) Al Jazeera Correspondent Episode credits: This episode was voiced by Nida Ibrahim, and producer by Marthe van der Wolf. Our sound designer is Alex Roldan. Our lead of audience development and engagement is Andrew Greiner and Munera AlDosari is our engagement producer. Alexandra Locke is The Take’s executive producer. Ney Alvarez is Al Jazeera's head of audio. Connect with us: @AJEPodcasts on X, Instagram, Facebook, and YouTube

Hamas said it marked an important and positive progress. Israel is demanding Hamas hand over the body of the last Israeli hostage.

In this Deep Dive episode, legal analyst Benyamin Moalem breaks down Prime Minister Netanyahu's high-stakes visit to the United States and his meetings with President Donald Trump, revealing what was gained — and what remains unresolved. The conversation covers U.S.–Israel coordination on Iran, Gaza, Hezbollah, and Syria, the pressure surrounding phase two of the Gaza deal, and the significance of Netanyahu offering Trump the Israel Prize amid talk of a future Nobel Peace Prize bid.Israel Daily News website: https://israeldailynews.orgYOUTUBE: https://youtube.com/@israeldailynews?si=UFQjC_iuL13V7tyQIsrael Daily News Patreon: https://www.patreon.com/shannafuldSupport our Wartime News Coverage: https://www.gofundme.com/f/independent-journalist-covering-israels-warLinks to all things IDN:⁠ https://linktr.ee/israeldailynews⁠

Anthologic Phase 2 Episode 002: Dead of Night (1972) Mark is joined by Scott and Steven from The Reel Britannia Podcast Feedback to: info@thegoodthebadandtheodd.com Or join the facebook group The Good The Bad And The Odd Or chat with Mark who runs the facebook account athttp://www.facebook.com/the-good-the-bad-and-the-odd See our youtube playlist for Anthologic phase 2: https://www.youtube.com/playlist?list=PLLj-os7wxResq3_or1cYf3_xgqIPJAh1K

Anthologic Phase 2 Episode 003: Nigel Kneale’s BEASTS (1976) Mark is joined by Scott and Steven from The Reel Britannia Podcast On youtube: Youtube Playlist: Anthologic Phase 2 Feedback to: info@thegoodthebadandtheodd.com Or join the facebook group The Good The Bad And The Odd Or chat with Mark who runs the facebook account athttp://www.facebook.com/the-good-the-bad-and-the-odd

Anthologic Phase 2 Episode 004: Inside Number 9 series 2 + bonus: The Devil In Christmas Mark is joined by Scott and Steven from The Reel Britannia Podcast On youtube: Youtube Playlist: Anthologic Phase 2 Feedback to: info@thegoodthebadandtheodd.com Or join the facebook group The Good The Bad And The Odd Or chat with Mark who runs the facebook account athttp://www.facebook.com/the-good-the-bad-and-the-odd

Anthologic Phase 2 Episode 002: Dead of Night (1972) Mark is joined by Scott and Steven from The Reel Britannia Podcast Feedback to: info@thegoodthebadandtheodd.com Or join the facebook group The Good The Bad And The Odd Or chat with Mark who runs the … Continue reading →

Anthologic Phase 2 Episode 003: Nigel Kneale’s BEASTS (1976) Mark is joined by Scott and Steven from The Reel Britannia Podcast On youtube: Youtube Playlist: Anthologic Phase 2 Feedback to: info@thegoodthebadandtheodd.com Or join the facebook group The Good The Bad And The Odd Or … Continue reading →

Anthologic Phase 2 Episode 004: Inside Number 9 series 2 + bonus: The Devil In Christmas Mark is joined by Scott and Steven from The Reel Britannia Podcast On youtube: Youtube Playlist: Anthologic Phase 2 Feedback to: info@thegoodthebadandtheodd.com Or join the facebook group The … Continue reading →

When it was time for Adam's birthday, he wanted to do as he always does; spread Eclipse Phase terror upon us. A group of Firewall agents are at an AGI research center. They have their target, an AGI named Idris. On the other side of the door is a Reaper Morph, however. Using their skills, and some handy flashbacks, can the agents keep their objective, and their heads...?Idris is a one shot designed by Adam for Eclipse Phase 2E, a game of transhumanism, horror, and science fiction. Eclipse Phase 2E is available at Posthuman's website, along with 1E and various supplements and merch.Adam - GMDan - EllisJared - Amaru TimotiLaura - BerkVince - Pivo

Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce a key clinical milestone, confirming that the first patient has been successfully dosed with intranasal foralumab in the company's Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer's disease (AD). This achievement follows the company's December 12, 2025 announcement that patient enrollment had begun, with first dosing expected imminently. The rapid progression from enrollment to dosing highlights strong site readiness and momentum for the study. The Phase 2 trial is designed to evaluate intranasal foralumab both as a standalone therapy and in combination with FDA-approved anti-amyloid treatments, including lecanemab (Leqembi®) and donanemab. By exploring combination therapy alongside monotherapy, Tiziana aims to assess whether targeting neuroinflammation can provide additive or complementary benefits to existing amyloid-reducing approaches. Elrifi explained that the trial is supported by compelling TSPO-PET imaging data, which demonstrate persistent and widespread microglial activation—a key marker of neuroinflammation—in patients with Alzheimer's disease. Notably, this neuroinflammatory activity has been shown to persist even after amyloid plaque reduction with therapies such as lecanemab. According to Elrifi, this evidence highlights a critical unmet need in Alzheimer's treatment: addressing residual neuroinflammation that may continue to drive disease progression. Intranasal foralumab is designed to modulate immune responses within the central nervous system and calm overactivated microglia, potentially reducing chronic inflammation associated with neurodegeneration. The intranasal delivery method is intended to provide targeted central nervous system exposure while minimizing systemic side effects. The Phase 2 study is a randomized, placebo-controlled trial assessing the safety, tolerability, and potential efficacy of intranasal foralumab in patients with early or mild Alzheimer's disease. Primary endpoints include changes in neuroinflammation as measured by TSPO-PET imaging, cognitive function outcomes, and biomarker changes related to amyloid and tau pathology. With the first patient now dosed, Tiziana Life Sciences advances into the next phase of clinical evaluation, positioning the company to generate meaningful data on whether addressing neuroinflammation—alone or in combination with anti-amyloid therapies—can improve outcomes for patients with early Alzheimer's disease. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #AlzheimersResearch #Neuroinflammation #BiotechNews #PETscan #ClinicalTrials #AlzheimersTreatment #PharmaUpdates #HealthcareInnovation

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce another major clinical milestone for the company, confirming that enrollment has been successfully completed in its Phase 2 clinical study evaluating the safety and efficacy of its Doxorubicin Microneedle Array (D-MNA), also known as SKNJCT-003, for the non-invasive treatment of nodular basal cell carcinoma (BCC) of the skin. The Phase 2 study has enrolled a total of 90 patients across nine clinical sites in the United States and is currently underway. Completion of enrollment represents a key step forward in Medicus Pharma's development strategy, positioning the company to advance discussions with regulators and accelerate progress toward later-stage trials. Dr. Bokhari explained that the company expects to report topline results from the SKNJCT-003 study in the first quarter of 2026. Following the release of these data, Medicus Pharma plans to pursue an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration in the first half of 2026 to discuss the next steps in the clinical and regulatory pathway. SKNJCT-003 is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate two dose levels of the Doxorubicin Microneedle Array compared with a placebo microneedle array (P-MNA). Participants are randomized on a 1:1:1 basis into three treatment arms: a placebo group receiving P-MNA, a low-dose group receiving 100 micrograms of D-MNA, and a high-dose group receiving 200 micrograms of D-MNA. The high-dose 200 microgram D-MNA represents the maximum dose previously tested in the company's Phase 1 safety and tolerability study, SKNJCT-001, which was successfully completed in March 2021. The Phase 2 trial builds on that foundation, aiming to further validate both safety and therapeutic effectiveness in a larger patient population. Medicus Pharma's microneedle-based approach is designed to deliver chemotherapy directly into skin lesions while avoiding the need for invasive surgery, offering the potential for improved patient comfort, cosmetic outcomes, and treatment accessibility. The successful completion of enrollment marks a critical inflection point as the company advances toward potential late-stage development and regulatory engagement. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews

Emission du jeudi 11 décembre 2025 :La phase 2 de la collection d'Hiver.

Israel is on edge again as three political shockwaves collide: Itamar Ben‑Gvir ignites global outrage by wearing a yellow noose pin in the Knesset debate over the death penalty for terrorists; Hamas kingpin Khaled Mashaal resurfaces in Istanbul with a chilling vow to eliminate Israel and reject any Trump‑brokered plan; and President Trump prepares to host Prime Minister Netanyahu at Mar‑a‑Lago to force momentum on “Phase 2” of his Gaza blueprint.

In this 56th edition of The World According to Irina Tsukerman, the bi-weekly geopolitical series on KAJ Masterclass LIVE, we break down escalating US –Venezuela tensions, the next phase of the Gaza plan, the Ukraine leadership crisis, and the China–Japan standoff reshaping Indo-Pacific strategy. Irina explains the forces driving these conflicts — from shifting war doctrines and intelligence rivalries to oil power plays and regional alignments. Viewers will walk away with a clear, fact-driven understanding of how today's flashpoints could redefine global security and the balance of power.About the guestIrina Tsukerman is a human rights and national security lawyer, geopolitical analyst, editor of The Washington Outsider, and president of Scarab Rising, Inc., a media and security and strategic advisory. Her writings and commentary have appeared in diverse US and international media and have been translated into over a dozen languages.Connect with Irina here:https://www.thewashingtonoutsider.com/https://www.linkedin.com/in/irina-tsukerman-4b04595/Catch up on earlier episodes in the playlist here:https://www.youtube.com/playlist?list=PLt7IEKOM1t1tKItNEVaStzsqSChTCGmp6Watch all our global politics content here:https://rumble.com/c/kajmasterclasshttps://www.youtube.com/@kajmasterclassPolitics=========================================

Tonix Pharmaceuticals Holdings CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug (IND) application for TNX-102 SL, enabling Tonix to begin clinical development of the drug for major depressive disorder (MDD) in adults. Dr. Lederman explained that the IND clearance allows Tonix to initiate the potentially pivotal Phase 2 HORIZON study — a 6-week, randomized, double-blind, placebo-controlled trial evaluating TNX-102 SL as a first-line monotherapy. The study will enroll approximately 360 adults across about 30 U.S. clinical sites. Participants must be 18 years or older and currently experiencing a moderate to severe major depressive episode. The trial will compare TNX-102 SL 5.6 mg, taken sublingually at bedtime, against placebo. The primary endpoint is change from baseline at Week 6 on the MADRS or Montgomery–Åsberg Depression Rating Scale total score. Secondary measures include global impression scores, anxiety assessments, and indicators of sleep disturbance. Tonix expects to begin enrolling patients in mid-2026. Dr. Lederman emphasized the significant need for new treatment options in MDD — a serious and widespread psychiatric condition affecting more than 21 million adults in the United States each year. Symptoms commonly include persistent sadness or loss of interest, sleep and appetite disruption, fatigue, impaired concentration, and feelings of worthlessness. These symptoms must be present for at least two weeks and cause meaningful impairment to daily life. Tonix aims to advance TNX-102 SL as a novel therapeutic option to address this substantial unmet medical need. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #kidneydisease #massachusettsgeneralhospital #massgeneral #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #DepressionTreatment #TNX102SL #MajorDepressiveDisorder #MentalHealthInnovation #SleepTherapy #FDAApproval #BiotechNews

Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification.Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/fulltextContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

AtaiBeckley NV CEO Dr Srinivas Rao joined Steve Darling from Proactive to discuss the company's official launch following the completion of the merger between Atai Life Sciences and Beckley Psytech, forming a new clinical-stage biopharmaceutical company focused on developing transformative treatments for mental health disorders. Rao said the combined company, now known as AtaiBeckley, brings together complementary expertise, proprietary technologies, and a robust clinical pipeline aimed at addressing treatment-resistant depression (TRD) and other mental health conditions. AtaiBeckley's lead program, BPL-003, a short-acting psychedelic compound, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for TRD. The company expects to meet with the FDA in the coming months to finalize Phase 3 trial plans, with pivotal studies anticipated to begin in Q2 2026. The company also reported positive topline results from the open-label extension (OLE) of its Phase 2b clinical trial of BPL-003 in TRD patients. A 12 mg dose administered eight weeks after an initial dose (0.3 mg, 8 mg, or 12 mg) produced rapid, robust, and sustained antidepressant effects lasting up to eight weeks. The Phase 2b trial consisted of an eight-week, quadruple-masked, dose-finding study followed by an eight-week OLE phase. Of the 126 patients who completed the core study, 107 entered the OLE. Patients who initially received 0.3 mg recorded a mean reduction in MADRS score of 14 points by Day 57.Those who received 8 mg or 12 mg demonstrated a mean reduction of 19 points, with a 63% responder rate and a 48% remission rate at Day 57. The safety and tolerability profile of BPL-003 in the OLE remained consistent with prior studies and comparable to other compounds within the psychedelic class. Beyond BPL-003, AtaiBeckley's pipeline includes VLS-01 (DMT buccal film) – in a Phase 2 trial for treatment-resistant depression, EMP-01 (R-MDMA) – in a Phase 2a trial for social anxiety disorder and a portfolio of preclinical 5-HT2A receptor agonists, including non-hallucinogenic neuroplastogens Rao said the newly merged entity is strategically positioned to become a leader in next-generation neuropsychiatric innovation, leveraging scientific depth and clinical momentum to bring novel treatments to patients with few or no existing options. #proactiveinvestors #ataibeckley #nasdaq #atai #clinicaltrial #bpl003 #depression #AtaiBeckley #BPL003 #PsychedelicTherapy #ClinicalTrials #MentalHealthInnovation #Phase2Results #5MeODMT #BiotechNews #DrugDevelopment #ProactiveInvestors

**Start Your Realty Ninja Website** Free Trial: https://www.realtyninja.com/tomBook a call w/Tom for Toronto: https://calendly.com/TomStoreyBook a call w/Steve for Greater Vancouver: https://calendly.com/stevekarrasch** Book your home inspection right now with Carson Dunlop ** https://carsondunlop.com/*** Need Home or Property Insurance? *** Use SQUARE ONE: Tenants, Landlords and Home Owners Save $20 with Square One Insurance using this link: https://www.squareone.ca/thetomstoreyshow?offer_code=TTSS- - - We experienced a housing crash in 2022, but is it over? Or is it just entering phase two?In this week's episode of The Tom Storey Show, Steve Karrasch and Tom Storey share a car ride on their way to a Real Estate conference and discuss the market, some car games and which restaurant has the best hot chicken sandwich. Enjoy!- - -*** Ontario Agents! Get Your Custom Branded TRESA Explainer Video TODAY! ***Order Here: https://tresavideo.ca/Promo Code: TOMSHOW

November 10, 2025 ~ John Maten, President of the Board of Directors of the Michigan WWII Legacy Memorial discusses the dedication of phase 2 tomorrow. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Chris Hughen sat down with Marc Surdyka to discuss phase 2 of ACL rehab. We recap the priorities from phase 1, outline the new goals of phase 2, cover how to build a structured and progressive resistance training plan, discuss when to implement running and plyometrics, and much more. Watch the full episode: https://youtu.be/0EpGJls1Yfw  Episode Resources: YouTube Video: ACL Rehab Phase 2 Blog: ACL Rehab Phase 2 Previous Episode: ACL Rehab Phase 1 --- Follow Us: YouTube: https://www.youtube.com/e3rehab  Instagram: https://www.instagram.com/e3rehab/ Twitter: https://twitter.com/E3Rehab --- Rehab & Performance Programs: https://store.e3rehab.com/  Newsletter: https://e3rehab.ck.page/19eae53ac1  Coaching & Consultations: https://e3rehab.com/coaching/  Mentoring: https://e3rehab.com/mentorship-intake-form/  Articles: https://e3rehab.com/articles/  --- Podcast Sponsor: Vivo Barefoot: Get 15% off all shoes! - https://www.vivobarefoot.com/e3rehab --- @dr.surdykapt @tony.comella @dr.nicolept @chrishughen @nateh_24 --- This episode was produced by Kody Hughes

In October 2025, Kodiak Copper announced the commencement of an additional metallurgical testwork program for its 100%-owned MPD Copper-Gold Porphyry Project in Southern British Columbia, building on the maiden test results received in Q2 2025.President, CEO, & Director Claudia Tornquist joins us to discuss the progress of the metallurgical testwork, key highlights from the MPD Project, and upcoming milestones.Learn more: https://kodiakcoppercorp.com/Watch the full YouTube interview here: https://youtu.be/kg_PKPvHCqMAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

In October 2025, Kodiak Copper announced the commencement of an additional metallurgical testwork program for its 100%-owned MPD Copper-Gold Porphyry Project in Southern British Columbia, building on the maiden test results received in Q2 2025.President, CEO, & Director Claudia Tornquist joins us to discuss the progress of the metallurgical testwork, key highlights from the MPD Project, and upcoming milestones.Learn more: https://kodiakcoppercorp.com/Watch the full YouTube interview here: https://youtu.be/kg_PKPvHCqMAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Explaining the “Implicit Phase” (months 1–5) of dating multiple women openly, continuing FB or MLTR dynamics while postponing labels and keeping communication clean. You'll learn how to signal non-exclusivity without lying, handle the “What are we?” question gracefully, and use evidence—not proof—to avoid drama and set up a smooth transition to Phase 3.

Das Wichtigste am Montag: In Berlin wird ein Zwischenbericht zur Suche nach einem Endlager für hochradiokativen Atommüll vorgestellt, in Istanbul diskutieren Außenminister aus Nahost über die zweite Phase des Gaza-Friedensplans – und in den Niederlanden wird das Briefwahlergebnis verkündet.

Want more MTM Vegas? Check out our Patreon for access to our exclusive weekly aftershow! patreon.com/mtmvegas Want to work with us? Reach out! inquiries at mtmvegas dot com Episode Description This week MGM's earnings call opened people's eyes to how the company is adjusting to current market conditions. While the goal was to raise prices over and over the past few years, the company is finally acknowledging some of their errors. Will they be able to cut back prices while keeping Wall Street Happy and what have they learned from this showdown? In other news a blockbuster lawsuit has been filed alleging that influencers and sweepstakes casinos are being honest. We also discuss: Disney's F1 Vegas invasion, Odyssey Noir carnival, Durango's official phase 2, Caesars extending locals deals, the Pinball Hall of Fame and how the Daily Mail has it out for Vegas. Episode Guide 0:00 Fremont Gorilla gets some love 0:32 Disney invades F1 & Vegas! 1:57 Will the real and fake Disney characters mix? 2:54 Big F1 lawsuit is dropped 4:05 Odyssey Noir Carnaval at Area 15 5:40 Strip auction fails & Daily Mail's weird coverage 6:58 The Pinball Hall of Fame is still a really cool place 8:05 Durango officially announced phase 3 expansion - New renders 9:57 Caesars extends local benefits until Christmas 11:02 Rio Executive denied for gaming license 13:10 Big lawsuit surrounding sweepstakes casinos 14:40 Do we need more regulations for influencers/social media casino marketing? 16:59 MGM earnings takeaways - We're sorry for overcharging 19:30 Recognizing different customers at different venues/price points 20:40 How will MGM raise revenue in this era of price cuts? Each week tens of thousands of people tune into our MtM Vegas news shows at http://www.YouTube.com/milestomemories. We do two news shows weekly on YouTube with this being the audio version. Never miss out on the latest happenings in and around Las Vegas! Enjoying the podcast? Please consider leaving us a positive review on your favorite podcast platform! You can also connect with us anytime at podcast@milestomemories.com.  You can subscribe on Apple Podcasts, Google Podcasts, Spotify or by searching "MtM Vegas" or "Miles to Memories" in your favorite podcast app. Don't forget to check out our travel/miles/points podcast as well!

In this conversation, Peter discusses significant updates regarding the Midnight project, focusing on the transition to phase two, which involves scavenger mining. He explains how users can participate in browser-based mining for $NIGHT tokens, the support from centralized exchanges like Kraken for token claims, and the opportunity to earn tokens through delegation to state pool operators in the Cardano ecosystem. The conversation emphasizes the importance of being prepared and aware of potential scams in the mining process.TakeawaysPhase two of the Midnight project involves scavenger mining.Users can mine $NIGHT tokens directly through their browsers.No technical setup is required for scavenger mining.Kraken will support the claim process for $NIGHT tokens.Users can earn $NIGHT tokens by delegating to state pool operators.The scavenger mining event will last for 21 days.30 million $NIGHT tokens will be available daily during the event.It's crucial to verify if your stake pool operator runs a Midnight node.Be cautious of potential scams in browser-based mining.Support for the channel is appreciated through various means.Chapters00:00 Introduction to Midnight Updates02:53 Scavenger Mining Explained05:48 Centralized Exchange Support for $NIGHT Tokens08:34 Earning $NIGHT Tokens through DelegationDISCLAIMER: This content is for informational and educational purposes only and is not financial, investment, or legal advice. I am not affiliated with, nor compensated by, the project discussed—no tokens, payments, or incentives received. I do not hold a stake in the project, including private or future allocations. All views are my own, based on public information. Always do your own research and consult a licensed advisor before investing. Crypto investments carry high risk, and past performance is no guarantee of future results. I am not responsible for any decisions you make based on this content.

Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer. Hear about the potential of HER3-targeted antibody-drug conjugates for brain metastases, why recruiting patients with active brain metastases to clinical trials is so important, and where the field is going next.Click here to read the full article: Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialClick here to read the full article: Patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode of Mining Stock Daily, Ian Wagner interviews Zayn Kalyan, CEO of Scorpio Gold, discussing the company's ambitious plans for the Manhattan Gold District Project in Nevada. They delve into the ongoing phase two drilling program, the potential for resource expansion, and the challenges of bringing historical resources into compliance. Zane emphasizes the company's strong financial position, the significance of their high-grade resources, and the overall market perception of Scorpio Gold.

Im Folgenden die Einschätzung von Olga Rodríguez, bekannte spanische Menschenrechtsaktivistin und Vor-Ort-Kennerin des Geschehens im Nahen Osten, insbesondere im Gazastreifen. Der Artikel erschien am 19. Oktober 2025 in der reichweitenstarken digitalen Zeitung elDiario.es, deren Mitbegründerin sie ist. Deutsche Übersetzung und Veröffentlichung durch Eckart Leiser mit dem Einverständnis der Autorin. Dieser Beitrag ist auch alsWeiterlesen

Vice-President Vance arrives in Israel for talks about Phase Two of President Trump's Gaza peace plan, as the President says if Hamas doesn't behave, "we're gonna go and eradicate them if we have to. They'll be eradicated;" Jonathan ... ...

Vice-President Vance arrives in Israel for talks about Phase Two of President Trump's Gaza peace plan, as the President says if Hamas doesn't behave, "we're gonna go and eradicate them if we have to. They'll be eradicated;" Jonathan ... ...

Vice-President Vance arrives in Israel for talks about Phase Two of President Trump's Gaza peace plan, as the President says if Hamas doesn't behave, "we're gonna go and eradicate them if we have to. They'll be eradicated;" Jonathan ... ...

Vice-President Vance arrives in Israel for talks about Phase Two of President Trump's Gaza peace plan, as the President says if Hamas doesn't behave, "we're gonna go and eradicate them if we have to. They'll be eradicated;" Jonathan ... ...

I'm so thrilled to be podcasting with you again!  I have so much to share with you, and so many great resources for you.  In this second phase of the podcast, we will be going deeper than ever before.  We will be talking about building your million dollar business without sacrificing family time, or you own sanity.  This is where nervous system mastery meets business strategy.  Let's dive in. Join Millionaires in the Making here. Book a strategy call here. And please leave a 5-star review!  I can't wait to talk soon.

We asked a body-level question: What does “enough” look and feel like—of time, resources, rest? What emerged isn't a finish line but a practice. Voices move from accumulation to sufficiency (“needs—with a handful of wants”), from schedules to presence (“time, not clocks”), from lone resilience to shared accountability. “Enough” shows up as a calmer nervous system and a commons that redistributes care—room to breathe, margin for the unknown, and infrastructures that make slowness livable. “Enough isn't a destination—it's a practice.” —Sophia F. The invitation is practical and collective: how do we design for capacity, not just velocity, so everyone has time to belong? This week, what single ritual could you add—or what metric could you retire—to build your capacity to rest and respond? Learn more about Deem at www.deemjournal.com

Zach Flood of Kenorland Minerals joins the podcast today for a thorough conversation on the Phase 2 work program at the South Uchi project with partners Auranova Resources. The company is following up on positive gold results earlier this year with another 6,000m program. Zach also provides a high-level summary of other work happening within the portfolio, including a highly anticipated mineral resource from the Frotet Project.

SummaryIn this conversation, Dr. Jeffery D. Skinner discusses the essential elements of church planting, emphasizing the importance of gathering a core team and shaping a launch community. He dispels the myth that only extroverted personalities can successfully plant churches, highlighting that success is measured by faithfulness rather than numbers or personality. The cross is presented as the central theme, serving as the foundation for identity, community, mission, and future hope in church planting.TakeawaysThe measure of success in church planting is faithfulness.Church planting is not limited to extroverted personalities.The cross must be the center of any church plant.A core team is essential for shaping the church's DNA.The launch team supports the church's initial growth.Community in church planting is forged through grace.The mission of the church is anchored in sacrificial love.The future of the church is gathered around the cross.Church planting embodies the future kingdom in the present.The cross shapes our identity as sons and daughters of the King.Become a supporter of this podcast: https://www.spreaker.com/podcast/echoes-through-eternity-with-dr-jeffery-skinner--5523198/support.Echoes Through Eternity Guiding church planters and pastors to plant seeds of prayer, holiness, and courage that outlast a lifetime. contact drjefferydskinner@protonmail.com

Phase 2 of The Change Leader's Roadmap is designed to inform, enroll and inspire your Project Community and all stakeholders of your project in making the effort successful. It highlights that the project will require changes in people's mindsets and behavior, which is a unique and essential expectation at project launch. This phase then develops more detailed plans for both Communications and Engagement so that your stakeholders understand and know how they will be asked to contribute during the change process. Communicating the project's desired outcomes, case for change and change strategy ensures this understanding as well as demonstrates that the old way of operating is about to end.Hosted by Ausha. See ausha.co/privacy-policy for more information.

[MovieNewsPodcast] ลือ! Avengers ใน Phase นี้อาจจะไม่ได้มีแค่ 2 เรื่อง

Anthologic Phase 2 Episode 001 Mark is joined by Scott and Steven from The Reel Britannia Podcast For the RSS Feed for this podcast, use: http://feeds.feedburner.com/anthologic Feedback to: info@thegoodthebadandtheodd.com Or join the facebook group The Good The Bad And The Odd Or chat with … Continue reading →

Anthologic Phase 2 Episode 001 Mark is joined by Scott and Steven from The Reel Britannia Podcast For the RSS Feed for this podcast, use: http://feeds.feedburner.com/anthologic Feedback to: info@thegoodthebadandtheodd.com Or join the facebook group The Good The Bad And The Odd Or chat with … Continue reading →

The trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.

Olympiacos has concluded phase 2 of its preseason in Holland and has returned to Greece. After the friendly against Union Berlin, Olympiacos faces its toughest tests of the preseason coming up against Napoli and Inter. We're chatting news, results from the friendlies, and how we think the squad is shaping up!

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA' and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab'.

The therapy delivers copies of the RORA gene to address multiple disease pathways.

Time Stamps:2:30 - The Black Pill6:45 - 5D Chess Bro13:55 - Trump's Nobel Peace Prize17:20 - "Are You Still Talking About Jeffrey Epstein?"23:20 - Secret Service Protects Pedophiles27:33 - VIP Driving Service Playbook46:35 - Comey/Brennan Investigation Misdirection50:44 - Gaza Concentration Camps57:22 - One Nation Under Blackmail1:00:48 - "And That's It on Epstein"1:02:55 - Postmortem/Call-in Portion1:09:22 - Palantir's Cloud Seeding ProjectVenture into the shadowy realms of power and secrecy with Already Dead, where hosts Jose Galison (@towergangjose) and Austin Picard (@theatrethugawp) dissect the intricate web of conspiracy, covert operations, and the underlying political machinations that might just be pulling the strings of our society.What to Expect:Live Listener Interaction: Call in to share your theories, ask burning questions, or discuss personal experiences related to the topics at hand. In-Depth Explorations: Each episode focuses on a different conspiracy or hidden aspect of political history, offering a platform to question and analyze what's often left unsaid. Thought-Provoking Guests: We invite individuals with insider knowledge or those who've taken the red pill to discuss topics that range from the fringe to the forefront of conspiracy culture. Critical Analysis of Current Affairs: We don't just report on events; we interpret them through the lens of parapolitics, looking for patterns and hidden agendas.Join Us:Every Tuesday at 9:30 PM ET, dive into the depths of the unknown with us. Subscribe, participate in our live call-ins, and be part of a community that seeks to understand the world beyond the surface narrative. Disclaimer: This podcast thrives on speculation, hypothesis, and the examination of alternative theories. It's meant to provoke thought and encourage personal research. Not all discussed is proven fact, but rather a call to question, explore, and understand.Warning: For those not ready to challenge their worldview, tread carefully. Once you enter the world of Already Dead, you might find that the truth is often already dead to the uninitiated. Welcome aboard, where curiosity is your guide.Please consider supporting our work-Austin's Patreon: https://www.patreon.com/c/TheUnderclassPodcastAustin's Spreaker: https://www.spreaker.com/podcast/the-underclass-podcast--6511540Austin's Rumble: https://rumble.com/user/TheUnderclassPodcastAustin's YouTube: https://www.youtube.com/@TheUnderclassPodcast#Phase2 #EpsteinCopium #BlackPilled #5DChess #TrumpsPeacePrize #NetanyahusNobelNomination #EpsteinDisclosure #LimitedHangout #FalseTransparency #PamBondiPropaganda #SecretService #JamesComey #JohnBrennan #DOJInvestigation #GazaConcentrationCamps #Rainmaker #Palantir #WeatherModification #CloudSeeding #GeoengineeringBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-underclass-podcast--6511540/support.

Corey, Jade & Caroline discuss several viewer questions from our FridayLive StreamsIf you have not read my book, “How To Be A 3% Man” yet, that would be a good starting place for you. It is available in Kindle, iBook, Paperback, Hardcover or Audio Book format. If you don't have a Kindle device, you can download a free eReader app from Amazon so you can read my book on any laptop, desktop, smartphone or tablet device. Kindle $9.99, iBook $9.99, Paperback $29.99 or Hardcover 49.99. Audio Book is Free $0.00 with an Audible membership trial or buy it for $19.95. Here is the link to Audible to get the audiobook version:http://bit.ly/CCW3ManHere is the link to Amazon to purchase Kindle, Paperback or Hardcover version:http://amzn.to/1XKRtxdHere is the link to the iBookstore to purchase iBook version:https://geo.itunes.apple.com/us/book/how-to-be-3-man-winning-heart/id948035350?mt=11&uo=6&at=1l3vuUoHere is the link to the iTunes store to purchase the iTunes audio book version:https://geo.itunes.apple.com/us/audiobook/how-to-be-a-3-man-unabridged/id1106013146?at=1l3vuUo&mt=3You can get my second book, “Mastering Yourself, How To Align Your Life With Your True Calling & Reach Your Full Potential” which is also available in Kindle $9,99, iBook $9.99, Paperback $49.99, Hardcover $99.99 and Audio Book format $24.95. Audio Book is Free $0.00 with an Audible membership trial. Here is the link to Audible to get the audiobook version:http://bit.ly/CCWMYHere is the link to Amazon to purchase Kindle, Paperback or Hardcover version:https://amzn.to/2TQV2XoHere is the link to the iBookstore to purchase iBook version:https://geo.itunes.apple.com/us/book/mastering-yourself-how-to-align-your-life-your-true/id1353139487?mt=11&at=1l3vuUoHere is the link to the iTunes store to purchase the iTunes audio book version:https://geo.itunes.apple.com/us/audiobook/mastering-yourself-how-to-align-your-life-your-true/id1353594955?mt=3&at=1l3vuUoYou can get my third book, “Quotes, Ruminations & Contemplations” which is also available in Kindle $9,99, iBook $9.99, Paperback $49.99, Hardcover $99.99 and Audio Book format $24.95. Audio Book is Free $0.00 with an Audible membership trial. Here is the link to Audible to get the audiobook version:https://www.audible.com/pd/B0941XDDCJ/?source_code=AUDFPWS0223189MWT-BK-ACX0-256995&ref=acx_bty_BK_ACX0_256995_rh_usHere is the link to Amazon to purchase Kindle, Paperback or Hardcover version:https://amzn.to/33K8VwFHere is the link to the iBookstore to purchase iBook version:https://books.apple.com/us/book/quotes-ruminations-contemplations/id1563102111?itsct=books_box_link&itscg=30200&ct=books_quotes%2C_ruminations_%26_contemplatio&ls=1Here is the link to the iTunes store to purchase the iTunes audio book version:https://books.apple.com/us/audiobook/quotes-ruminations-contemplations-volume-i-unabridged/id1567242372?itsct=books_box_link&itscg=30200&ct=audio-books_quotes%2C_ruminations_%26_contem&ls=1Here is the website link to purchase Official Coach Corey Wayne branded merchandise (T-Shirts, Mugs, etc.):https://coreywayneshop.com/Click the link below to book phone/Skype (audio only) coaching with me personally:https://understandingrelationships.com/products/phone-coachingClick the link below to make a donation via PayPal to support my work:

Team insiders Ryan Mink and Garrett Downing report back after a hard hat tour of M&T Bank Stadium and talk with President Sashi Brown, Senior Vice President of Stadium Operations Rich Tamayo, and Senior Vice President of Marketing Brad Downs about what goes into the massive project.See omnystudio.com/listener for privacy information.